Leerink sets $36 price target for Latigo Biotherapeutics
Latigo Biotherapeutics was initiated at an Outperform rating by Leerink Partners, with a $36.00/share price target announced, per TradingView News.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.